当前位置: 首页 > 期刊 > 《中国当代医药》 > 2013年第16期
编号:13161043
TL—1A和IL—17在类风湿关节炎中的作用及其临床意义(4)
http://www.100md.com 2013年6月5日 《中国当代医药》 2013年第16期
     [21] Hochberg MC,Tracy JK,Hawkins-Holt M,et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab,etanercept,and infliximab when added to methotrexate in patients with active rheumatoid arthritis[J]. Ann Rheum Dis,2003,62(2):13-16.

    [22] Klareskog L,Heijde D,De Jager JP,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial[J]. Lancet,2004,363(9410):675-681.

    [23] Genovese MC,Bathon JM,Fleischmann RM,et al. Longterm safety,efficacy,and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis[J]. J Rheum,2005,32(7):1232-1242.

    [24] 赵金霞,刘湘源. TNF-α拮抗剂治疗类风湿关节炎疗效预测指标的研究进展[J]. 中华临床医师杂志,2010,4(4): 447-449.

    [25] Hueber W,Tomooka BH,Batliwalla F,et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis[J]. Arthritis Res Ther,2009,11(3):76.

    (收稿日期:2013-05-02 本文编辑:袁 成), http://www.100md.com(薛妍 林星 王长连)
上一页1 2 3 4